October 15, 2019
This is to announce the transfer of Marketing Authorization of DIAZOXIDE Capsules 25 mg “MSD” in Japan from MSD K.K. (Headquarters: Chiyoda-ku, Tokyo, Representative Director and President: Jannie Oosthuizen, hereinafter referred to as “MSD K.K.”) to OrphanPacific, Inc. (Headquarters: Minato-ku, Tokyo, Representative Director and President: Philippe Auvaro, hereinafter referred to as “OrphanPacific”) on November 12, 2019.
OrphanPacific have been selling the product and providing and collecting product information of DIAZOXIDE Capsules 25 mg “MSD”, as a distributor from April 1, 2017.
Following this transfer, the product name will be changed to DIAZOXIDE Capsules 25 mg “OP”.
DIAZOXIDE Capsules 25 mg “MSD” is the only medicine in Japan that has been approved for the indication of “hyperinsulinemic hypoglycemia” associated with congenital hyperinsulinemia, insulinoma, and other conditions.
By the transfer of this product, OrphanPacific will improve the lineup in the treatment of pediatric metabolic and endocrine diseases, which are one of the focused areas of activity as it would further contribute to the treatment of rare diseases.
Contact departments of inquiries for this announcement
OrphanPacific, Inc. Corporate Planning Department Tel: 03-6779-8151
PDF Announcement of Marketing Authorization Transfer and Product Name Change of DIAZOXIDE Capsules 25 mg "MSD"